

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 07405699869, email: info@vivanzabiosciences.com, web: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057

April 25, 2023

To,
Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai — 400001

BSE Scrip Code- 530057

Subject: Outcome of the Board Meeting

Dear Sir/Madam,

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Tuesday, April 25, 2023 at Registered Office of the Company has inter alia considered and approved the followings:

- 1. Audited Standalone and Consolidated Financial Results along with Audit Report of the Company for the Quarter and Financial Year ended on 31st March, 2023 which is enclosed herewith as Annexure-1.**
- 2. Resignation of Ms. Manali Patel as Non-Executive, Independent Director of the Company**

The Board took note of the resignation tendered by Ms. Manali S. Patel (DIN: 08531916) who has resigned from the position of the Independent Director of the Company with effect from April 25th, 2023.

Disclosure required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A of Part A of Schedule III to the said Regulations, with regard to change in Directors and Key Managerial Personnel is given herein under:

S NO	Disclosure Requirements	Details
1.	Reason for change: Resignation	Ms. Manali S. Patel (DIN: 08531916) has expressed her intention to resign as Independent Director of the Company w.e.f. April 25 th , 2023 due to personal reason and other professional commitments, as mentioned in her resignation letter dated April 25 th , 2023.
2.	Date of Cessation	End of Business Hours on April 25 th , 2023.

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 07405699869, email: info@vivanzabiosciences.com, web: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057

3.	Other Directorship and Category	NONE
----	---------------------------------	------

Further, the Company has received confirmation from Ms. Manali S. Patel (DIN: 08531916) that there are no material reasons for her resignation other than those, mentioned in the resignation letter dated April 25th, 2023. The said confirmation received is enclosed herewith as Annexure-2.

3. Appointment of Ms. Apeksha Vyas as Additional Non-executive Independent Director of the Company

Ms. Apeksha Vyas (DIN: 09469295) has been appointed as an Additional Director (Non Executive, Independent) on the Board of the Company with effect from April 25th, 2023 pursuant to Section 149, 150, 152 read with Schedule IV and Section 161(1) read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and other applicable provisions thereof, subject to the approval of shareholders at the ensuing General Meeting of the Company or within a time period of three months from the date of appointment, whichever is earlier.

Ms. Apeksha Vyas is not related to any of the Directors of the Company.

A brief profile of Ms. Apeksha Vyas is as follows:

She is Qualified Company Secretary. She has 3+ year experience in Corporate Secretarial work. She has completed her Bachelors in Commerce in the year 2015 from H.A.C.C and LL.M (IPR) from I. M. Nanavati, GLS Campus in the year 2018.

4. Resignation of Mr. Girish Bhatt as Managing Director of the Company

The Board took note of the resignation tendered by Mr. Girish Bhatt (DIN: 02207645) who has resigned from the position of the Managing Director of the Company with effect from April 25th, 2023.

Disclosure required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A of Part A of Schedule III to the said Regulations, with regard to change in Directors and Key Managerial Personnel is given herein under:

S NO	Disclosure Requirements	Details
1.	Reason for change: Resignation	Mr. Girish Bhatt (DIN: 02207645) has expressed his intention to resign as Managing Director of the Company w.e.f. April 25 th , 2023 due to personal reason and other professional commitments, as mentioned in his resignation letter dated April 25 th , 2023.

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 07405699869, email: info@vivanzabiosciences.com, web: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057

2.	Date of Cessation	End of Business Hours on April 25 th , 2023.
3.	Other Directorship and Category	NONE

Further, the Company has received confirmation from Mr. Girish Bhatt (DIN: 02207645) that there are no material reasons for his resignation other than those, mentioned in the resignation letter dated April 25th, 2023. The said confirmation received is enclosed herewith as Annxure-3.

5. Appointment of Mr. Jayendra Mehta as Managing Director of the Company

Ms. Jayendra Mehta (DIN: 08210602) has been appointed as an Managing Director on the Board of the Company with effect from April 25th, 2023 pursuant to Section 149, 150, 152 read with Schedule IV and Section 161(1) read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and other applicable provisions thereof, subject to the approval of shareholders at the ensuing General Meeting of the Company or within a time period of three months from the date of appointment, whichever is earlier.

Ms. Jayendra Mehta is not related to any of the Directors of the Company.

A brief profile of Mr. Jayendra Mehta is as follows:

He has 20+ years of experience in the field of pharma and biosciences domain. Mr. Mehta is expected to join us as Managing Director not later than 25th April, 2023. He has over 20+ years of senior financial experience and operational and leadership skills gained through management roles.

6. Reconstitution of Various Committee/s of the Board w.e.f. April 25, 2023 as below:

I. AUDIT COMMITTEE:

S.No	Name of the Director	Status in Committee	Nature of Directorship
1.	Mr. Shah SD.	Chairman	Non-Executive Independent Director
2.	Ms. Apeksha Vyas	Member	Additional Non-Executive Non-Independent Director
3.	Mr. Jayendra Mehta	Member	Executive Director

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
Phone: 07405699869, email: info@vivanzabiosciences.com, web: www.vivanzabiosciences.com
CIN: L24110GJ1982PLC005057

II. NOMINATION AND REMUNERATION COMMITTEE:

S.No	Name of the Director	Status in Committee	Nature of Directorship
1.	Mr. Shah SD.	Chairman	Non-Executive Non- Independent Director
2.	Ms. Apeksha Vyas	Member	Additional Non-Executive Independent Director
3.	Mr. Parikh H. A.	Member	Non-Executive Director

III. STAKEHOLDER'S RELATIONSHIP COMMITTEE:

S.No	Name of the Director	Status in Committee	Nature of Directorship
1.	Mr. Shah SD.	Chairman	Non-Executive Non- Independent Director
2.	Ms. Apeksha Vyas	Member	Additional Non-Executive Non- Independent Director
3.	Mr. Jayendra Mehta	Member	Executive Director

The meeting of Board of Directors of the Company commenced at 06:30 P.M. and concluded at 07:00 P.M.

You are requested to kindly take the same on record and acknowledge.

Thanking You.

For, Vivanza Biosciences Limited

Avinash Bhojwani
Digitally signed by
Avinash Bhojwani
Date: 2023.04.25
19:02:38 +05'30'

Avinash Bhojwani
Company Secretary & Compliance Officer
Membership No.: A53955

Encl: As above

SHIVAM SONI & CO.

Chartered Accountants

Office Address : B-904, Titanium City Centre (Corporate Park), Prahladnagar Road,
Satellite, Ahmedabad – 380015. Mobile : 9409519080 Email : ca.shivam94@gmail.com

UDIN: 23178351BGXIQQ9973

To,
Board of Directors
M/s Vivanza Biosciences Limited

Report on the Audit of the Consolidated Annual Financial Results Opinion

We have audited the accompanying statement of quarterly and year to date consolidated financial results of **M/s Vivanza Biosciences Limited** ("Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter and year ended March 31, 2023, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of reports of other auditors on separate audited financial statements of the subsidiary, the aforesaid consolidated annual financial results:

- A. includes the annual financial results for the year ended 31st March 2023, of the following entities:

Sr. No.	Particulars	Name of the Entity
1.	Subsidiary	Vivanza Life sciences Private Limited

- B. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard and
- C. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the consolidated net Profit and other comprehensive income and other financial information of the Group for the year ended 31 March 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the 'ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and that obtained by the other auditor in terms of their report referred to in paragraph of the Other Matters section below, is sufficient and appropriate to provide a basis for our opinion.



SHIVAM SONI & CO.

Chartered Accountants

Office Address : B-904, Titanium City Centre (Corporate Park), Prahladnagar Road,
Satellite, Ahmedabad – 380015. Mobile : 9409519080 Email : ca.shivam94@gmail.com

Responsibility of Management for the Consolidated Annual Financial Results

The consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements. The Holding Company's management and Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these annual financial results that give a true and fair view of the financial position, financial performance, changes in equity

and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Directors of the Holding Company, as aforesaid. In preparing the consolidated annual financial results, the respective Board of Directors of the companies included in the Group is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is also responsible for overseeing the financial reporting process of each company.

Auditor's Responsibility for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the consolidated annual financial results.

As a part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.



SHIVAM SONI & CO.

Chartered Accountants

Office Address : B-904, Titanium City Centre (Corporate Park), Prahladnagar Road,
Satellite, Ahmedabad – 380015. Mobile : 9409519080 Email : ca.shivam94@gmail.com

- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management
- Conclude on the appropriateness of Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any Significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all the relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards

We also performed procedures in accordance with the circular No CIRJCFD/CMD1/44/2019 issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable



SHIVAM SONI & CO.

Chartered Accountants

Office Address : B-904, Titanium City Centre (Corporate Park), Prahladnagar Road,
Satellite, Ahmedabad – 380015. Mobile : 9409519080 Email : ca.shivam94@gmail.com

Other Matters

We did not audit the annual financial statements of one subsidiary included in the Statement for the year ended on that date, as considered in the Statement. These Annual Financial Statements have been audited by other auditor whose Audit report has been furnished to us by the management, and our opinion in so far as it relates to the amounts and disclosures Include in respect of this subsidiary is based solely on the audit report of such other auditor, and the procedure performed by us as stated in paragraph above.

Place: Ahmedabad
Date: 25th April, 2023



For, SHIVAM SONI & Co.
Chartered Accountants
FRN: 152477W

Shivam

CA Shivam Soni
Proprietor
Membership No: 178351

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.

CIN : L24110GJ1982PLC005057

Tel No.: 079-26870953 Email : info@vivanzabiosciences.com Website : www.vivanzabiosciences.com

STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2023

(Rs. in Lacs except per share data)

Particulars	Quarter Ended			Year Ended	
	31/03/2023	31/12/2022	31/03/2022	31/03/2023	31/03/2022
	Audited	Unaudited	Audited	Audited	Audited
1 Income from Operations					
(a) Revenue from operations	823.85	586.03	584.53	1780.69	1040.02
(b) Other Income	12.42	1.04	29.47	47.54	82.89
Total Income	836.27	587.07	614.00	1828.24	1122.90
2 Expenses					
(a) Cost of Materials consumed	0.00	0.00	0.00	0.00	0.00
(b) Purchase of stock-in-trade	858.62	523.57	420.41	1655.27	1142.77
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	-55.95	-5.33	138.00	-4.65	-177.42
(d) Employee benefits expense	8.69	8.25	9.63	35.08	29.62
(e) Finance Cost	10.52	11.12	9.58	41.86	40.56
(f) Depreciation and amortisation expense	0.06	0.07	0.38	0.26	0.74
(g) Other expenses	12.88	3.54	27.26	28.77	53.28
Total Expenses	834.81	541.22	605.26	1756.59	1089.56
3 Profit/(Loss) before exceptional items and tax (1-2)	1.45	45.84	8.73	71.65	33.34
4 Exceptional Items	0.00	0.00	28.70	0.00	0.00
5 Profit/(Loss) before tax (3-4)	1.45	45.84	-19.97	71.65	33.34
6 Tax Expense					
(a) Current tax	11.80	0.00	0.11	11.80	0.11
(b) Deferred tax	0.01	0.00	-0.07	0.01	-0.07
Total Tax Expenses	11.81	0.00	0.04	11.81	0.04
7 Profit / (Loss) for the period from continuing operations (5-6)	-10.36	45.84	-20.00	59.83	33.30
8 Profit (Loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
9 Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
10 Profit (Loss) from discontinuing operations (after	0.00	0.00	0.00	0.00	0.00
11 Other Comprehensive Income					
A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
Other Comprehensive Income for the period	0.00	0.00	0.00	0.00	0.00
12 Total Comprehensive Income for the period	-10.36	45.84	-20.00	59.83	33.30
Paid-up equity share capital (Face value of Rs. 1/- each)	400	400	400	400	400
13 Other Equity	-	-	-	-	-50.75
15 Earnings Per Share (before extraordinary items) (not annualised):					
(a) Basic	-0.26	1.15	-0.50	1.50	0.83
(b) Diluted	-0.26	1.15	-0.50	1.50	0.83
16 Earnings Per Share (after extraordinary items) (not annualised):					
(a) Basic	-0.26	1.15	-0.50	1.50	0.83
(b) Diluted	-0.26	1.15	-0.50	1.50	0.83

Notes:

- The above standalone audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on April 25, 2023. The Audit under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Audit Report does not contain any observation which could have an impact on the results for the quarter/year ended March 31, 2023.
- The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.
- The Company is in the business of Pharmaceuticals and Agro Trading & Consultancy related Activities.

For, VIVANZA BIOSCIENCES LIMITED

Jainil Bhatt
C.F.O.

PAN: AJDPB2629L

Date : 25/04/2023
Place : Ahmedabad

VIVANZA BIOSCIENCES LIMITED			
STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES			
(Rs.in Lacs)			
Particulars		As at 31/03/2023	As at 31/03/2022
A	ASSETS		
	1 Non-current Assets		
(a)	Property, Plant and Equipment	67.95	68.21
(b)	Other Intangible assets (including Goodwill)	163.54	163.54
(c)	Capital work in progress	-	-
(d)	Intangible assets under development	-	-
(e)	Financial Assets :		
(i)	Investments	0.25	0.25
(ii)	Deferred tax assets (Net)	0.10	0.11
(iii)	Loans	1.10	19.62
(f)	Other non-current assets	59.33	59.33
	Sub-total - Non-current Assets	292.27	311.06
	2 Current Assets		
(a)	Inventories	247.46	242.81
(b)	Financial Assets :		
(i)	Investments	-	-
(ii)	Trade Receivables	1,247.94	784.04
(iii)	Cash and Cash Equivalents	14.09	5.51
(iv)	Loans	413.15	192.87
(c)	Other current assets	32.75	19.91
	Sub-total - Current Assets	1,955.40	1,245.13
	TOTAL - ASSETS	2,247.67	1,556.19
B	EQUITY AND LIABILITIES		
	Shareholders' Funds		
(a)	Share Capital	400.00	400.00
(b)	Other Equity	9.10	(50.75)
	Sub-total - Shareholders' Funds	409.10	349.25
	1 Liabilities		
	Non-current Liabilities		
(a)	Financial Liabilities :		
(i)	Borrowings	143.28	259.65
(b)	Deferred Tax Liabilities (Net)	-	-
(c)	Provisions	-	-
(d)	Other Non - Current Liabilities	-	-
	Sub-total - Non-current liabilities	143.28	259.65
	2 Current Liabilities		
(a)	Financial Liabilities :		
(i)	Borrowings	656.42	291.15
(ii)	Trade Payables	954.93	548.48
(iii)	Other Financial Liabilities	-	-
(b)	Provisions	15.84	3.99
(c)	Other Current Liabilities	68.10	103.67
	Sub-total - Current Liabilities	1,695.29	947.29
	TOTAL - EQUITY AND LIABILITIES	2,247.67	1,556.19



VIVANZA BIOSCIENCES LIMITED

Cashflow Statement

(Rs.in Lacs)

Particulars	01-04-2022 to 31-03-2023	01-04-2021 to 31-03-2022
A Cash flow from Operating Activities		
Net Profit Before Tax	71.65	33.34
Adjustments for:		
Add Depreciation	0.26	0.74
Less Dividend Income	-	-
Add Interest Expense	41.86	40.56
Less Short Term Capital Gain (Mutual Fund)	-	-
Operating Profit / (Loss) before Working Capital Changes	<u>113.76</u>	<u>74.65</u>
Adjustments for:		
Increase/(Decrease) in Trade Payables	406.44	162.01
Increase/(Decrease) in Other Current Liabilities	(35.57)	4.05
Increase/(Decrease) in Provisions	11.85	(2.98)
(Increase)/Decrease in Trade Receivables	(463.91)	(158.98)
(Increase)/Decrease in short term loans & advances	18.52	90.93
Increase/(Decrease) in Borrowing	(116.38)	259.65
(Increase)/Decrease in inventories	(4.65)	(177.46)
(Increase)/Decrease in other current assets	(12.84)	(5.07)
Cashflow generated from Operating Activities	<u>(82.77)</u>	<u>246.79</u>
Income Tax Paid (Net of Refund)	11.80	0.11
Net Cashflow generated from Operating Activities A	<u><u>(94.57)</u></u>	<u><u>246.68</u></u>
B Cash flow from Investment Activities		
Purchase of Property , Plant and Equipment	-	-
Sale of Property , Plant and Equipment	-	-
Sale of Investments	-	-
Purchase of Investments	-	-
Share Application Money Received Back	-	-
Dividend Income	-	-
Net Cashflow generated from Investments Activities B	<u><u>-</u></u>	<u><u>-</u></u>
C Cash flow from Financing Activities		
Share Listing & Processing Fees	-	-
Interest Expenses	(41.86)	(40.56)
(Increase)/Decrease in other non-current assets	0.00	(59.33)
(Increase) /Decrease in Short term Loans & Advances (Assets)	(220.27)	(87.41)
Increase /(Decrease) in Borrowings (Liabilities)	365.27	(60.39)
Increase/(Decrease) in non current liabilities	-	-
Increase/(Decrease) in other financial liabilities	-	-
Net Cashflow generated from Financing Activities C	<u><u>103.15</u></u>	<u><u>(247.70)</u></u>
Net Change in Cash & Cash Equivalents (A+B+C)	<u><u>8.58</u></u>	<u><u>(1.02)</u></u>
Opening Cash & Cash Equivalents	<u>5.51</u>	<u>6.53</u>
Closing Cash & Cash Equivalents	<u><u>14.09</u></u>	<u><u>5.51</u></u>



SHIVAM SONI & CO.

Chartered Accountants

Office Address : B-904, Titanium City Centre (Corporate Park), Prahladnagar Road,
Satellite, Ahmedabad – 380015. Mobile : 9409519080 Email : ca.shivam94@gmail.com

UDIN: 23178351BGXIQF1849

To,
The Board of Directors
M/s Vivanza Biosciences Limited

Opinion

We have audited the accompanying standalone annual financial results of M/s Vivanza Biosciences Limited (hereinafter referred to as 'the Company') for the quarter and year ended March 31, 2023 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Statement:

- (i) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) give a true and fair view in conformity with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with Companies (Indian Accounting Standards) Rules, 2015, as amended, and other accounting principles generally accepted in India, of Net Profit and other comprehensive income and other financial information of the Company for the year ended March 31, 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Board of Directors' Responsibilities for the Standalone Financial Results

This Statement have been prepared on the basis of the standalone annual financial statements. The Company's Board of Directors are responsible for the preparation and presentation of this Statement that give a true and fair view of the net loss and other comprehensive income in accordance with the Indian Accounting Standards prescribed under Section 133 of the Act read with Companies (Indian Accounting Standards) Rules, 2015, as amended issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Board of Directors of the Company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due



SHIVAM SONI & CO.

Chartered Accountants

Office Address : B-904, Titanium City Centre (Corporate Park), Prahladnagar Road,
Satellite, Ahmedabad – 380015. Mobile : 9409519080 Email : ca.shivam94@gmail.com

to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Company, as aforesaid.

In preparing the Statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the Override of internal control

Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.



SHIVAM SONI & CO.

Chartered Accountants

Office Address : B-904, Titanium City Centre (Corporate Park), Prahladnagar Road,
Satellite, Ahmedabad – 380015. Mobile : 9409519080 Email : ca.shivam94@gmail.com

We communicate with those charged with governance of the Company of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The Statement include the results for the quarter ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" which were subject to limited review by us.

Place: Ahmedabad
Date: 25th April, 2023



For, SHIVAM SONI & Co.
Chartered Accountants
FRN: 152477W

Shivam
CA Shivam Soni
Proprietor
Membership No: 178351

VIVANZA BIOSCIENCES LIMITED

Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054.
CIN : L24110GJ1982PLC005057

Tel No.: 079-26870953 Email : info@vivanzabiosciences.com Website : www.vivanzabiosciences.com

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2023 (Rs. in Lacs except per share data)

Particulars	Quarter Ended			Year Ended	
	31/03/2023	31/12/2022	31/03/2022	31/03/2023	31/03/2022
	Audited	Unaudited	Audited	Audited	Audited
1 Income from Operations					
(a) Revenue from operations	601.90	480.10	559.68	1420.71	914.75
(b) Other Income	12.42	1.04	0.75	38.68	82.81
Total Income	614.32	481.14	560.43	1459.39	997.56
2 Expenses					
(a) Cost of Materials consumed	0.00	0.00	0.00	0.00	0.00
(b) Purchase of stock-in-trade	573.43	419.13	396.71	1234.05	1030.87
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	5.25	-0.36	136.96	61.52	-182.73
(d) Employee benefits expense	6.51	6.78	7.43	26.19	11.98
(e) Finance Cost	10.47	11.12	9.58	41.82	40.56
(f) Depreciation and amortisation expense	0.06	0.07	0.38	0.26	0.74
(g) Other expenses	12.25	2.66	26.83	26.83	49.72
Total Expenses	607.98	439.40	577.90	1390.67	951.16
3 Profit/(loss) before exceptional items and tax (1-2)	6.34	41.73	-17.47	68.72	46.41
4 Exceptional Items	0.00	0.00	0.00	0.00	0.00
5 Profit/(Loss) before tax (3-4)	6.34	41.73	-17.47	68.72	46.41
6 Tax Expense					
(a) Current tax	11.80	0.00	0.11	11.80	0.11
(b) Deferred tax	0.01	0.00	-0.07	0.01	-0.07
Total Tax Expenses	11.81	0.00	0.04	11.81	0.04
7 Profit / (Loss) for the period from continuing operations (5-6)	-5.47	41.73	-17.51	56.91	46.37
8 Profit (Loss) from discontinuing operations	0.00	0.00	0.00	0.00	0.00
9 Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
10 Profit (Loss) from discontinuing operations (after	0.00	0.00	0.00	0.00	0.00
11 Other Comprehensive Income					
A(i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
B (i) Items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
Other Comprehensive Income for the period	0.00	0.00	0.00	0.00	0.00
12 Total Comprehensive Income for the period	-5.47	41.73	-17.51	56.91	46.37
Paid-up equity share capital (Face value of Rs. 1/- each)	400	400	400	400	400
13				39.81	-17.12
14 Other Equity					
Earnings Per Share (before extraordinary items) (not annualised):					
(a) Basic	-0.14	1.04	-0.44	1.42	1.16
(b) Diluted	-0.14	1.04	-0.44	1.42	1.16
Earnings Per Share (after extraordinary items) (not annualised):					
(a) Basic	-0.14	1.04	-0.44	1.42	1.16
(b) Diluted	-0.14	1.04	-0.44	1.42	1.16

Notes:

1. The above standalone audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on April 25, 2023. The Audit under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been carried out by the statutory auditors. The Audit Report does not contain any observation which could have an impact on the results for the quarter/year ended March 31, 2023.

2. The Company adopted the Indian Accounting Standards ('Ind AS') effective 1st April, 2017 (transition date 1st April, 2016). The financial results have been prepared in accordance with Ind AS as prescribed under Section 133 of the Companies Act, 2013 read with the relevant Rules issued there under.

3. The Company is in the business of Pharmaceuticals and Agro Trading & Consultancy related Activities.

For, VIVANZA BIOSCIENCES LIMITED

Jainil Bhatt
C.F.O.

PAN: AJDPB2629L

Date : 25/04/2023
Place : Ahmedabad

VIVANZA BIOSCIENCES LIMITED		
STATEMENT OF STANDALONE ASSETS AND LIABILITIES		
(Rs.in Lacs)		
Particulars	As at 31/03/2023	As at 31/03/2022
A ASSETS		
1 Non-current Assets		
(a) Property, Plant and Equipment	0.13	0.38
(b) Other Intangible assets	-	-
(c) Capital work in progress	-	-
(d) Intangible assets under development	-	-
(e) Financial Assets :		
(i) Investments	191.45	191.45
(ii) Deferred tax assets (Net)	0.10	0.11
(iii) Loans		
(f) Other non-current assets	59.33	59.33
Sub-total - Non-current Assets	251.01	251.28
2 Current Assets		
(a) Inventories	161.02	222.54
(b) Financial Assets :		
(i) Investments		-
(ii) Trade Receivables	1,218.42	735.10
(iii) Cash and Cash Equivalents	10.45	1.89
(iv) Loans	370.40	190.29
(c) Other current assets	32.75	19.81
Sub-total - Current Assets	1,793.03	1,169.63
TOTAL - ASSETS	2,044.04	1,420.91
B EQUITY AND LIABILITIES		
Shareholders' Funds		
(a) Share Capital	400.00	400.00
(b) Other Equity	39.81	(17.12)
Sub-total - Shareholders' Funds	439.81	382.88
1 Liabilities		
Non-current Liabilities		
(a) Financial Liabilities :		
(i) Borrowings	-	-
(b) Deferred Tax Liabilities (Net)	-	-
(c) Provisions	-	-
(d) Other Non - Current Liabilities	-	-
Sub-total - Non-current liabilities	-	-
2 Current Liabilities		
(a) Financial Liabilities :		
(i) Borrowings	656.42	442.02
(ii) Trade Payables	865.99	548.48
(iii) Other Financial Liabilities	-	-
(b) Provisions	14.75	2.95
(c) Other Current Liabilities	67.07	44.57
Sub-total - Current Liabilities	1,604.23	1,038.02
TOTAL - EQUITY AND LIABILITIES	2,044.04	1,420.91



VIVANZA BIOSCIENCES LIMITED

Cashflow Statement

(Rs.in Lacs)

Particulars	01-04-2022 to 31-03-2023	01-04-2021 to 31-03-2022
A Cash flow from Operating Activities		
Net Profit Before Tax	68.72	46.41
Adjustments for:		
Add Depreciation	0.26	0.74
Less Dividend Income	-	-
Add Interest Expense	41.82	40.56
Less Short Term Capital Gain (Mutual Fund)	-	-
 Operating Profit / (Loss) before Working Capital Changes	110.79	87.71
Adjustments for:		
Increase/(Decrease) in Trade Payables	317.51	162.01
Increase/(Decrease) in Other Current Liabilities	22.50	(2.74)
Increase/(Decrease) in Provisions	11.80	(2.40)
(Increase)/Decrease in Trade Receivables	(483.31)	(124.30)
(Increase)/Decrease in short term loans & advances	-	-
Increase/(Decrease) in Borrowing	-	-
(Increase)/Decrease in inventories	61.52	(182.73)
(Increase)/Decrease in other current assets	(12.94)	(5.07)
 Cashflow generated from Operating Activities	27.86	(67.53)
Income Tax Paid (Net of Refund)	11.79	0.19
Net Cashflow generated from Operating Activities A	16.07	(67.72)
B Cash flow from Investment Activities		
Purchase of Property , Plant and Equipment	-	-
Sale of Property , Plant and Equipment	-	-
Sale of Investments	-	-
Purchase of Investments	-	-
Share Application Money Received Back	-	-
Dividend Income	-	-
Net Cashflow generated from Investments Activities B	-	-
C Cash flow from Financing Activities		
Share Listing & Processing Fees	-	-
Interest Expenses	(41.82)	(40.56)
(Increase)/Decrease in other non-current assets	-	0.07
(Increase) /Decrease in Short term Loans & Advances (Assets)	(180.10)	(3.12)
Increase /(Decrease) in Borrowings (Liabilities)	214.39	(42.16)
Net Change In Unsecured Loans Taken	-	150.87
Increase/(Decrease) in other financial liabilities	-	-
Net Cashflow generated from Financing Activities C	(7.52)	65.10
 Net Change in Cash & Cash Equivalents (A+B+C)	8.55	(2.61)
Opening Cash & Cash Equivalents	1.89	4.51
Closing Cash & Cash Equivalents	10.45	1.89



MANALI PATEL**846, TRIJO VAS, NARANPURA GAM, NARANPURA, AHMEDABAD-380013**

Date: 25.04.2023

To,
The Board of Directors,
Vivanza Biosciences Limited
403, Sarthik 2, Opp. Rajpath Club,
S.G. Highway, Ahmedabad-380054

Subject: Resignation from the post of Independent Director of the Company.

Dear Sir/Madam,

I Manali S. Patel, hereby tender my resignation from the post of an Independent Director of the Company (Vivanza Biosciences Limited) with immediate effect. The resignation is purely on account of personal reason and other professional commitments and there is no other material reason apart from the one mentioned herewith.

I would like to convey my deep sense of appreciation and feeling of gratitude for the support I received from all the Directors on the Board and Senior Executives of the Company during the period of my association with the Company. I wish all the very best to the Company.

Further, I request you to complete all the formalities with regard to my resignation including filing of required forms with the Ministry of Corporate Affairs and intimating to the other relevant Authorities as may be required.

Thanking You

Yours sincerely,

Manali

MANALI S. PATEL
(DIN: 08531916)



Accepted 25.04.2023

Jain

GIRISH BHATT

30 Gopinath flat, Behind dharnidhar derasar, Vasna, Paldi, Ahmedabd-380007

Date: 25.04.2023

To,
The Board of Directors,
Vivanza Biosciences Limited
403, Sarthik 2, Opp. Rajpath Club,
S.G. Highway, Ahmedabad-380054

Subject: Resignation from the post of Managing Director of the Company.

Dear Sir/Madam,

I Girish Bhatt, hereby tender my resignation from the post of a Managing Director of the Company (Vivanza Biosciences Limited) with immediate effect. The resignation is purely on account of personal reason and other professional commitments and there is no other material reason apart from the one mentioned herewith.

I would like to convey my deep sense of appreciation and feeling of gratitude for the support I received from all the Directors on the Board and Senior Executives of the Company during the period of my association with the Company. I wish all the very best to the Company.

Further, I request you to complete all the formalities with regard to my resignation including filing of required forms with the Ministry of Corporate Affairs and intimating to the other relevant Authorities as may be required.

Thanking You

Yours sincerely,

Girish Bhatt

GIRISH BHATT
(DIN: 02207645)



Accepted 25.04.2023

Jain